Bellicum discontinues phase 1/2 trials and initiates evaluation of strategic alternatives

Houston, march 14, 2023 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq: blcm), today announced its decision to discontinue its ongoing phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its gocar-t cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. the trials for bpx-601 and bpx-603 are being discontinued following the company's assessment of the risk/benefit profile of bpx-601 in combination with rimiducid.
BLCM Ratings Summary
BLCM Quant Ranking